Retraction: Clinical Impact of De-Regulated Notch-1 and Notch-3 in the Development and Progression of HPV-Associated Different Histological Subtypes of Precancerous and Cancerous Lesions of Human Uterine Cervix (PLoS ONE (2014) 9:6 (e98642) DOI: 10.1371/journal.pone.0098642);Clinical impact of de-regulated Notch-1 and Notch-3 in the development and progression of HPV-associated different histological subtypes of precancerous and cancerous lesions of human uterine cervix

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Tripathi, Richa ^a   Rath, Gayatri ^b   Jawanjal, Poonam ^b   Sharma, Shweta ^a   Singhal, Pallavi ^a   Bhambhani, Suresh ^a   Hussain, Showket ^a   Bharadwaj, Mausumi ^a  

^a INSTITUTE OF CYTOLOGY AND PREVENTIVE ONCOLOGY   (India)

^b SAFDARJUNG HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

NOTCH1 RECEPTOR; NOTCH3 RECEPTOR; NOTCH RECEPTOR; NOTCH1 PROTEIN, HUMAN; NOTCH3 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER GROWTH; CELL MEMBRANE; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; DISEASE SEVERITY; DOWN REGULATION; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION; UTERINE CERVIX; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; VIRUS CARCINOGENESIS; WART VIRUS; CARCINOGENESIS; CLASSIFICATION; DISEASE COURSE; GENE EXPRESSION REGULATION; METABOLISM; PAPILLOMA VIRUS; PATHOLOGY; PHYSIOLOGY; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX TUMOR; VIROLOGY;

CARCINOGENESIS; CARCINOMA, SQUAMOUS CELL; CERVIX UTERI; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PAPILLOMAVIRIDAE; RECEPTOR, NOTCH1; RECEPTORS, NOTCH; UTERINE CERVICAL NEOPLASMS;

EID: 84902603350     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0272116     Document Type: Erratum

References (60)

1. Das BC, Hussain S, Nasare V, Bharadwaj M (2008) Prospects and prejudices of human papillomavirus vaccines in India. Vaccine 26: 2669-79.
2. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, et al. (2013). Globacan 2012, 1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No.11.
3. Singh N, Sobti RC, Suri V, Nijhawan R, Sharma S, et al. (2013) Down-regulation of tumor suppressor gene PML in uterine cervical carcinogenesis: Impact of human papillomavirus infection (HPV). Gynecol Oncol 28(3):420-6.
4. Molano M, Brule A, Plummer M, Weiderpass E, Posso H, et al. (2003) HPV Study Group: Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Amô Jô Epidemiol 158: 486-494 (Pubitemid 37022847)
5. Artavanis TS, Rand MD, Lake RJ (1999) Notch: cell fate control and signal integration in development. Science 284: 770-776. (Pubitemid 29291335)
6. Le Borgne R, Remaud S, Hamel S, Schweisguth F (2005) Two distinct E3 ubiquitin ligases have complementary functions in the regulation of delta and serrate in Drosophila. PLoS Biol 3: e96.
7. Weinmaster G (1997) The ins and outs of Notch. Mol Cell Neuroscience 9(2): 91-102
8. Miele L, Miao H, Nickoloff BJ (2006) Notch as a novel cancer therapeutic target. Curr Cancer Drug Targets 6: 313-23 (Pubitemid 43961866)
9. Cheng F, Pekkonen P, Ojala PM (2012) Instigation of Notch in the pathogenesis of Kaposi's sarcoma-associated herpes virus and other human tumor viruses. Future Microbiol 7(10): 1191-205.
10. Tzoneva G, Ferrando AA (2012) Recent advances on Notch in T-ALL. Curr Top Microbiol Immunol 360: 163-82.
11. Pang RT, Leung CO, Ye TM, Liu W, Chiu PC, et al. (2010) MicroRNA-34a suppresses invasion through downregulation of Notch-1 and Jagged-1 in cervical carcinoma and choriocarcinoma cells. Carcinogenesis 31(6): 1037-44.
12. Brennan K, Brown AM (2003) Is there a role for Notch signalling in human breast cancer? Breast Cancer Res 5(2): 69-75. (Pubitemid 36348099)
13. Leong KG, Karsan A (2006) Recent insights into the role of Notch in tumorigenesis. Blood 107(6): 2223-33. (Pubitemid 43345539)
14. Yamaguchi N, Oyama T, Ito E, Satoh H, Azuma S, et al. (2008) Notch-3 pathway plays crucial roles in the proliferation of ErbB2-negative human breast cancer cells. Cancer Res 68: 1881-8. (Pubitemid 351416574)
15. Choi JH, Park JT, Davidson B, Morin PJ, Shih IeM, et al. (2008) Jagged-1 and Notch-3 juxtacrine loop regulates ovarian tumor growth and adhesion. Cancer Res 68: 5716-23.
16. Hu W, Lu C, Dong HH, Huang J, Shen DY, et al. (2011) Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer. Cancer Res 71 (18): 6030-9.
17. Yeasmin S, Nakayama K, Rahman MT, Rahman M, Ishikawa M, et al. (2010) Expression of nuclear Notch-3 in cervical squamous cell carcinomas and its association with adverse clinical outcomes. Gynecol Oncol117(3): 409-16.
18. Bahnassy AA, Zekri AR, Alam El, Din HM, Aboubakr AA, et al. (2006) The role of cyclins and cyclins inhibitors in the multistep process of HPV-associated cervical carcinoma. Jô Egypt Natl Canc Inst 18(4): 292-302.
19. Shepherd JH (1996) Cervical and vulva cancer: changes in FIGO definitions of staging. Brô Jô Obstet Gynaecol 103: 405-6.
20. Tripathi SC, Matta A, Kaur J, Grigull J, Chauhan SS, et al. (2010) Nuclear S100A7 is associated with poor prognosis in head and neck cancer. PLoS One 5(8): e11939.
21. Hussain S, Bharti AC, Salam I, Bhat MA, Mir MM, et al. (2009) Transcription factor AP-1 in esophageal squamous cell carcinoma: alterations in activity and expression during human papillomavirus infection. BMC Cancer 9: 329.
22. Sobti RC, Singh N, Hussain S, Suri V, Nijhawan R, et al (2011) Aberrant promoter methylation and loss of suppressor of cytokine signalling-1 gene expression in the development of uterine cervical carcinogenesis. Cell Oncol 34(6): 533-43.
23. Singh N, Sobti RC, Suri V, Nijhawan R, Sharma S, et al.(2013). Down-regulation of tumor suppressor gene PML in uterine cervical carcinogenesis: Impact of human papillomavirus infection (HPV) Gynecol Oncol128(3):420-6.
24. Kwok S, Higuchi R (1989). Avoiding false positives with PCR. Nature 339: 237-238.
25. American Cancer Society (2012) Cancer Facts & Figures. Atlanta, GA: American Cancer Society
26. Gibb RK, Martens MG (2011). The Impact of Liquid-Based Cytology in Decreasing the Incidence of Cervical Cancer. Rev Obst & Gynecol 4 (1): S2-S11.
27. Swan J, Breen N, Coates RJ, Rimer BK, Lee NC (2003). Progress in cancer screening practices in the United States. Results from the 2000 national health interview survey. Cancer 97: 1528-40. (Pubitemid 36297783)
28. Harry TK, Felicia MS, Ngugen S (2006). A needs assessment of barriers to cervical cancer screening in Vietnamese American health care providers. Californianô Jô Health Promotion 4: 146-56.
29. Gakidou E, Nordhagen S, Obermeyer Z (2008). Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities. PloS Med 5: 132
30. Sarkar M, Konar H, Raut DK (2010) Symptomatology of gynecological malignancies: experiences in the gynecology out-patient clinic of a tertiary care hospital in Kolkata, India. Asian Pacô Jô Cancer Prev 11: 785-91.
31. Sarkar M, Konar H, Raut DK (2012) Gynecological malignancies: epidemiological characteristics of the patients in a tertiary care hospital in India. Asian Pacô Jô Cancer Prev 13: 2997-3004.
32. Sarkar M, Konar H, Deepak R (2013) Clinicopathological features of gynecological malignancies in a tertiary care hospital in eastern India: Importance of strengthening primary health care in prevention and early detection. Asian Pacificô Jô Cancer Prev 14 (6): 3541-3547
33. Shekhar S, Sharma C, Thakur S, Raina N (2013) Cervical Cancer Screening: Knowledge, Attitude and Practices among Nursing Staff in a Tertiary Level Teaching Institution of Rural India. Asian Pacô Jô Cancer Prev14(6):3641-3645
34. Bhatla N, Gulati A, Mathur SR, Rani S, Anand K, et al. (2009) Evaluation of cervical screening in rural North India. Intô Jô Gynaecol Obstet 105: 145-149.
35. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136. (Pubitemid 120035062)
36. Sobti RC, Singh N, Hussain S, Suri V, Bharti AC, et al. (2009) Over-expression of STAT3 in HPV-mediated cervical cancer in a North Indian population. Mol Cell Biochem 330(1-2): 193-9.
37. Burchell AN, Winer RL, de Sanjose S, Franco EL (2006) Epidemiology and transmission dynamics of genital HPV infection. Vaccine 24 (3): 52-61.
38. Gupta S, Kumar P, Tyagi A, Sharma K, Kaur H, et al. (2012) Modern Approaches to Prevention and Control of Cancer of the Uterine Cervix in women Journal of the Indian Institute of Science 92 (3): 353-364.
39. Bhatla N, Dar L, Rajkumar Patro A, Kumar P, Pati SK, et al. (2008) Human papillomavirus-type distribution in women with and without cervical neoplasia in north India. Intô Jô Gynecol Pathol 27(3): 426-30.
40. Hussain S, Bharadwaj M, Nasare V, Kumari M, Sharma S, et al. (2012) Human papillomavirus infection among young adolescents in India: Impact of vaccination. Jô Med Virol 84(2): 298-305.
41. Hausen HZ (1996) Papillomavirus infections: a major cause of human cancers. Biochem Biophys Acta 1288: 55-78.
42. Kohaar I, Thakur N, Salhan S, Batra S, Singh V, et al. (2007) TNF-308G/A polymorphism as a risk factor for HPV associated cervical cancer in Indian population. Cell Oncol 29: 249-56. (Pubitemid 46855705)
43. Franceschi S, Rajkumar T, Vaccarella S, Gajalaskshmi V, Sharmila A, et al. (2003) Human papillomavirus and risk factors for cervical cancer in Chennai, India: A case-control study. Intô Jô Cancer 107 (1): 127-133. (Pubitemid 37100096)
44. Thomas MB (2014) Systemic and Targeted Therapy for Biliary Tract Tumors and Primary Liver Tumors. Surg Oncol Clinô Nô Am 23(2): 369-381.
45. Aithal MG, Rajeswari NJ (2013) Role of Notch signalling pathway in cancer and its association with DNA methylation. Genet 2(3): 667-75.
46. Teruya-Feldstein J (2010) The Immunohistochemistry laboratory: looking at molecules and preparing for tomorrow. Arch.Pathol Lab Med 134(11): 1659-65.
47. Talora C, Sgroi DC, Crum CP, Dotto G P (2002) Specific down-modulation of Notch1 signalling in cervical cancer cells is required for sustained HPV-E6/E7 expression and late steps of malignant transformation. Genes Dev 6: 2252-2263 (Pubitemid 35013088)
48. Rangarajan A, Syal R, Selvarajah S, Chakrabarti O, Sarin A, et al. 2001) Activated Notch-1 cooperates with papillomavirus oncogenes in transformation and generates resistance to apoptosis on matrix withdrawal through PKB/Akt. Virology 286: 23-30 (Pubitemid 32675462)
49. Bharadwaj M, Hussain S, Tripathi R, Singh N, Mehrotra R (2014) Human Papillomavirus (HPV): Diagnosis and Treatment. In Animal Biotechnology: Models in Discovery and Translation, Verma A and Singh A, editors. Elsevier. pp.95-120
50. Bertrand FE, Angus W, Partis WJ, Sigounas G (2012) Developmental pathways in colon cancer Crosstalk between WNT, BMP, Hedgehog and Notch. Cell Cycle 11(23): 4344-4351
51. Tanigaki K, Nogaki F, Takahashi J, Tashiro K, Kurooka H, et al. (2001) Notch-1 and Notch-3 instructively restrict bFGF responsive multipotent neural progenitor cells to an astroglial fate. Neuron 29: 45-55. (Pubitemid 32108721)
52. Funahashi Y, Shawber CJ, Vorontchikhina M, Sharma A, Outtz HH, et al. (2008) Notch regulates the angiogenic response via induction of VEGFR-1. Jô Angiogenes Res 2: 3.
53. Konishi J, Kawaguchi KS, Vo H, Haruki N, Gonzalez A, et al. (2007) Gamma-secretase inhibitor prevents Notch-3 activation and reduces proliferation in human lung cancers. Cancer Res 67: 8051-7. (Pubitemid 47395139)
54. Curry CL, Reed LL, Golde TE, Miele L, Nickoloff BJ, et al. (2005) Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. Oncogene 24: 6333-44. (Pubitemid 41486467)
55. Moellering RE, Cornejo M, Davis TN, Del Bianco C, Aster JC, et al. (2009) Direct inhibition of the Notch transcription factor complex. Nature 462: 182-188.
56. Kefas B, Comeau L, Floyd DH, Seleverstov O, Godlewski J, et al. (2009) The neuronal microRNA miR-326 acts in a feedback loop with notch and has therapeutic potential against brain tumors. Jô Neurosci 29: 15161-15168.
57. Song G, Zhang Y, Wang L (2009) MicroRNA-206 targets Notch-3, activates apoptosis and inhibits tumor cell migration and focus formation. Jô Biol Chem 284 (3): 1921-31927.
58. Gilbert CA, Hermance N, Daou MC, et al. (2010) Glioma treatment with temozolomide and Notch inhibition suppresses neurosphere formation and xenograft formation. AACR Meeting Abstracts.
59. Wang J, Wakeman TP, Lathia JD, Hjelmeland AB, Wang XF, et al. (2010). Notch promotes radioresistance of glioma stem cells. Stem Cells 28: 17-28.
60. Wang C, Yao N, Lu CL, Li D, Ma X (2010) Mouse microRNA-124 regulates the expression of HES-1 in P19 cells. Front Biosci 2: 127-132.